ALCAM and melanoma: The elevated expression of CD44, along with CD20, was earlier reported by Cordaro et al. in melanoma cells resistant to dabrafenib [38], while high levels of CD166 corresponded with poorer prognosis in patients suffering from uveal melanoma [39].